A sense of wonder, attempt to understand life (biology), and chain of unanswered childhood questions began to converge when Charles made his first observation of leukemia cells under the microscope as an undergraduate at UC Davis. His love for cell biology grew through isolation, differentiation, and genetic modification of various stem cell populations that he investigated in graduate studies at UC Davis. Charles sought ways to provide stem cells with a microenvironment that could regulate the intricate balance between self-renewal and lineage commitment. This effort led to the development of the hyper-crosslinked carbohydrate polymer (HCCP), which became the basic building block of a tissue engineering programs aimed to develop a personalized, regenerative therapy. After the initial development and proof-of-concept studies at UC Davis, he founded Molecular Matrix, Inc in 2011 to bring the HCCP technology to patients with bone-related diseases through regulatory studies. Charles works closely with researchers, surgeons, business developers, financial and regulatory professionals at Molecular Matrix, Inc. to create and maintain a corporate culture that fosters integrity, innovation, and passion for improving the quality of life for people in need.

Founder, CEO, and Chairman of the Board

Charles Lee, PhD

Mr. Keefer brings over 25 years of medical industry experience to the team, providing unique insight to the specific challenges associated with bringing new products to market.  Mr. Keefer has been involved in numerous product launches, providing strategic direction that resulted in successful commercialization. Mr. Keefer is a seasoned sales leader with a consistent record of generating growth in the healthcare industry through tactical sales process enhancements providing new business development and sales team leadership. He is an expert at elevating startup organizations and positioning them for growth, M&A, or IPO by drawing on a unique clinical and business-oriented approach. Mr. Keefer has demonstrated success in facilitating clinical results, reducing complications and shaping a brand name through clinical expertise. Mr. Keefer is a skilled provider of advanced training that results in the development and retention of top-performing talent.

COO, Board Member

James H. Keefer

Mr. Wink graduated magna cum laude with an accounting degree from California State University, Sacramento, in 1991. Chris is a licensed CPA in the State of California, and also holds Series 7 and 63 securities licenses, and a California real estate salesperson license. Most recently, Chris was awarded the personal financial specialist credential from the American Institute of Certified Public Accountants (AICPA). Mr. Wink is a member of the American Institute of Certified Public Accountants (AICPA), the California Society of Certified Public Accountants, finance committee member of Y-Me National Breast Cancer Organization, the Kiwanis Club of Greater Davis, and various other organizations.

Chief Financial Officer

Christopher Wink, CPA, PFS

Mr. Whitlock has over 25 years of orthopedics industry experience, in addition to being a co-founder of Path4 Ventures and an Operating Venture Partner with PTV Sciences. He co-founded Spinal Restoration, and LDR Spine USA, where he served as President. Steve also served on the executive team at Ortho Kinematics as Vice President of Product Development, and still maintains observer rights to the board.  Steve was very involved with development, funding and commercialization stages at each of these companies, and participated in the successful exit of LDR through Public Offering and later $1 billion acquisition by Zimmer Biomet. Mr. Whitlock began his healthcare industry career with Sulzer / Centerpulse Orthopedics, where he held executive management roles in Research and Development, New Business Development, and Global Products in the areas of total joints, sports medicine, trauma, and orthobiologics. He was part of the executive team responsible for a major company turnaround leading to a $3.2 billion acquisition by Zimmer in 2003. Mr. Whitlock has been instrumental in bringing many technologies to the U.S. orthopedic and spine markets, and holds 15 issued patents. Mr. Whitlock holds a B.S. in Mechanical Engineering degree from Texas A&M University and an MBA from the Embry-Riddle Aeronautical University.

Chief Commercial Officer

Steven I. Whitlock, MBA

Mr. Kapitan brings 30 years of experience in regulatory affairs and the development of quality control systems.  He has also been the lead is numerous research/clinical studies. His expertise covers clinical regulatory compliance, study design, and FDA submission expertise. His managerial and leadership roles in conjunction with his vast experience in a broad array of clinical and research arenas, make him exceptionally qualified to conduct the fda submission activities for novel products in development at Molecular Matrix.

Clinical and Regulatory Affairs

John Kapitan  |  Kapstone Medical

Dr. Blackman is a retired pediatric spine surgeon who continues to engage in new technology development.  He is the inventor of the first minimally invasive deformity correction system where scoliosis correction was accomplished through a series of tubes.  This technology was acquired by Medtronic.  Dr. Blackman plays a key role in the surgeries, and training of operating room staff.  Dr. Blackman also provides invaluable expertise in the development of new technologies and procedures.

Surgical Advisor, Trainer, Consultant

Ronald Blackman, MD

Dr. Groverman graduated from the University of California Davis as a Doctor of Veterinary Medicine in 1958 and has been a practicing veterinarian ever since. As an active member of his community, Dr. Groverman has served on numerous boards for more than forty years including Santa Rosa Memorial Alliance, Sonoma County 4-H, Association of California Hospital Districts, Waugh Elementary School and the Sonoma County Fair boards. Dr. Groverman served as President of the American Shropshire Sheep Association and has authored many scientific articles for national sheep and veterinary publications.

Director of Preclinical Development

Fred Groverman, DVM


Office Hours

Monday-Friday: 4:00 AM - 6:00 PM PDT

P: 1-916-376-9404


3410 Industrial Blvd, Ste 103

West Sacramento, CA 95691

  • White LinkedIn Icon
  • White Facebook Icon
  • White Twitter Icon

© 2018 Molecular Matrix, Inc. All rights reserved.